logo
logo

Healionics Raises $4.7M Equity Round To Support Commercialization Of Stargraft Vascular Graft

May 13, 2021•over 4 years ago

Amount Raised

$4.7 Million

Round Type

seed

Seattle

Description

Healionics Corporation, a private medical device company, announced today the completion of a $4.7M equity financing round led by Keiretsu Capital. The company also announced the conversion to equity of $5.2M in previously outstanding notes and interest.

Company Information

Company

Healionics Corporation

Location

Seattle, Washington, United States

About

Healionics is a clinical-stage company addressing the critical need for safer, more reliable means to access the bloodstream for dialysis in patients with kidney failure. Its STARgraft vascular graft is designed to resist the problems of infection and occlusion suffered by current devices. The company also has an exciting product pipeline based on its platform STAR® biomaterial, which has a unique ability to resist both infection and scarring, two problems that affect all implanted devices. www.healionics.com SOURCE Healionics Corporation